Evidence map›Paper›PMID 31854069›Full record

Trial reportJournal of viral hepatitis2020

Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs.

Risha Irvin, Geetanjali Chander, Kathleen M Ward, Sean Manogue, Oluwaseun Falade-Nwulia, Juhi Moon, Catherine G Sutcliffe, Sherilyn Brinkley, Taryn Haselhuhn, Stephanie Katz and 5 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of viral hepatitis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Risha IrvinDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-5953-9316
Geetanjali ChanderDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kathleen M WardDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sean ManogueDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Oluwaseun Falade-NwuliaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2321-2295
Juhi MoonDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Catherine G SutcliffeDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Sherilyn BrinkleyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Taryn HaselhuhnDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Stephanie KatzDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kayla HerneDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lilian ArteagaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David L ThomasDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shruti H MehtaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Mark S SulkowskiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2145-6352
Johns Hopkins University · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Management/Hepatitis C/HIV-infected and Uninfected IDU'sR01DA016065 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2003 to 2018
$8.0M
HIV HCV Coinfection Antiviral Therapy and FibrosisR37DA013806 · NIDA · JOHNS HOPKINS UNIVERSITY · PI THOMAS, DAVID L · 2010 to 2019
$7.0M
1/4 Alcohol Research Consortium in HIV-Administrative Core (ARCH-AC)U24AA020801 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI CHANDER, GEETANJALI, MCCAUL, MARY E · 2011 to 2021
$3.5M
Mentoring and Patient Oriented Research at the Nexus of Unhealthy Alcohol Use and HIVK24AA027483 · NIAAA · UNIVERSITY OF WASHINGTON · PI GEETANJALI CHANDER · 2019 to 2026
$1.3M
Patient Oriented Research in Hepatitis C-infected Injection Drug UsersK24DA034621 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2012 to 2022
$1.2M
The impact of social networks on hepatitis C transmission and care access in people who inject drugsK23DA041294 · NIDA · JOHNS HOPKINS UNIVERSITY · PI FALADE-NWULIA, OLUWASEUN · 2016 to 2020
$924k
Johns Hopkins Center for AIDS Research P30AI094189National Institute of Allergy and Infectious Diseases P30AI094189NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1TR001079NIAAA NIH HHS K24 AA027483NIAAA NIH HHS K24AA027483NIAAA NIH HHS U24 AA020801NIAAA NIH HHS U24AA020801NIAID NIH HHS P30 AI094189NIDA NIH HHS K23 DA041294NIDA NIH HHS K23DA041294NIDA NIH HHS K24 DA034621NIDA NIH HHS K24DA034621NIDA NIH HHS R01 DA016065NIDA NIH HHS R01DA16065NIDA NIH HHS R37 DA013806NIDA NIH HHS R37DA013806NIDA NIH HHS U01 DA036935NIDA NIH HHS U01DA036935NIH HHS K23DA041294NIH HHS K24AA027483NIH HHS K24DA034621NIH HHS R01DA16065NIH HHS R37DA013806NIH HHS U01DA036935NIH HHS U24AA020801
6 · The paper itself

Abstract

We investigated the prevalence and impact of heavy alcohol use on the hepatitis C virus (HCV) care continuum amongst HIV/HCV co-infected persons who use drugs. In the CHAMPS study, 144 HIV/HCV co-infected persons were randomized to contingent cash incentives, peer mentors and usual care to evaluate the impact on HCV care. Alcohol use was ascertained using the 10-item AUDIT (hazardous: male ≥8, female ≥4) and phosphatidylethanol (PEth) (heavy: ≥50 ng/mL), an alcohol biomarker. Log binomial regression was used to evaluate the association between heavy alcohol use and failure to initiate treatment and to achieve sustained virologic response (SVR). Of the 135 participants with PEth data, median age was 55 years, 59% were male, 92% were Black, 91% reported a history of drug use, and 97% were on antiretroviral therapy. Hazardous drinking was reported on AUDIT by 28% of participants, and 35% had heavy alcohol use by PEth. Of the 47 individuals with a PEth ≥50 ng/mL, 23 (49%) reported no or minimal alcohol use by AUDIT. HCV treatment was initiated in 103 of 135 participants, and SVR was achieved in 92%. PEth ≥50 ng/mL (Relative Risk [RR] 0.72, 95% CI 0.35-1.48) was not significantly associated with failure to initiate HCV treatment or failure to achieve SVR (RR 0.85, 95% CI 0.46-1.57).In conclusion, alcohol use was common and frequently not detected by self-report. However, heavy alcohol use, even when measured objectively, was not associated with failure to initiate HCV treatment or to achieve cure.

Indexed as

Alcohol DrinkingHepatitis CHIV InfectionsSubstance-Related DisordersCoinfectionDisclosureFemaleHepacivirusHumansMaleMentoringMiddle AgedMotivationPeer GroupSelf Reportalcohol usehepatitis C care continuumhepatitis C virusHIVsubstance use

Identifiers

PMID31854069
PMCPMC7890377
OpenAlexW2996726779

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.